cancer oncologyHelsinn, a Swiss pharmaceutical group focused on building quality cancer care announces a collaboration with Lyfebulb, a patient-centric company that empowers patient entrepreneurs to deliver innovative products and solutions to patients living with chronic disease. 

The collaboration will focus on recognising patient entrepreneurs who are developing innovative ideas and concepts for better management of cancer using pharmaceuticals, biotechnology, medical devices and nutritional supplements.

Linking entrepreneurs with senior team and board members from Helsinn and Lyfebulb will spotlight the entrepreneurs’ efforts and ideas, and provide professional discussion, direction, and inspiration.   

“This collaboration with Helsinn is an important milestone for Lyfebulb in our efforts to enhance patient-driven innovation in chronic disease,” said Dr Karin Hehenberger, CEO and Founder of Lyfebulb. 

“Continuing to build on the concept of patient entrepreneurs and the expansion of our Lyfebulb Entrepreneur Circle are key components to our overall corporate strategy and clearly aligned with our Mission. These new entrepreneurs may help to transform the lives of patients.” 

Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: “At Helsinn, we are committed to improving the quality of everyday lives of cancer patients and placing the patient at the center of everything we do is part of our daily work. My team and I look forward to the unique opportunity to learn from and be inspired by the patient entrepreneurs.”